Mankind Pharma Ltd

About Mankind Pharma Ltd

Mankind Pharma Ltd. is a leading Indian pharmaceutical company manufacturing and marketing a diverse portfolio of pharmaceutical formulations and popular consumer healthcare products. With a strong focus on the domestic market, it aims to provide affordable and quality medicines, establishing a significant presence across various therapeutic segments.

Key Financial Ratios of Mankind Pharma Ltd

• P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Mankind Pharma Ltd's P/E ratio (TTM) is 47.76, compared to the industry median of 30.91 and large cap median of 44.19.

• P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Mankind Pharma Ltd's P/B ratio is 5.97, compared to the industry median of 3.69 and large cap median of 6.64.

• P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Mankind Pharma Ltd's P/S ratio is 6.84, compared to the industry median of 3.74 and large cap median of 6.84.

• PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Mankind Pharma Ltd's PEG ratio is 6.03.

• EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Mankind Pharma Ltd's EV/EBITDA ratio is 25.95.

• Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Mankind Pharma Ltd's ROE is 11.89%.

• Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Mankind Pharma Ltd's ROA is 12.88%.

• Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Mankind Pharma Ltd's ROCE is 14%.

• Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Mankind Pharma Ltd's operating margin is 25.33%.

• Net Margin: Net margin shows what percentage of revenue converts into final net profit. Mankind Pharma Ltd's net margin is 13.57%.

• Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Mankind Pharma Ltd's current ratio is 0.72.

• Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Mankind Pharma Ltd's debt-to-equity ratio is 0.18.

• Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Mankind Pharma Ltd's interest coverage ratio is 4.65.

• Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Mankind Pharma Ltd's DPS is ₹0.

• Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Mankind Pharma Ltd's EPS is -3.98.

(Source line: "Ratios as of 24 Sept 2026, based on last traded price of ₹2356.50. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")

Key Facts

• Founded: 1995

• Headquarters: New Delhi, Delhi

• Core Offerings: Pharmaceutical Formulations, Consumer Healthcare Products, APIs, Prescription Medicines, OTC Products

• Stock Listing: NSE (MANKIND), BSE (543904)

• Promoter: Ramesh C. Juneja, Rajeev Juneja, Sheetal Arora

History of Mankind Pharma Ltd

Mankind Pharma was founded in 1995 by Mr. Ramesh C. Juneja and Mr. Rajeev Juneja with a vision to provide affordable healthcare to the masses. The company rapidly expanded its presence across India, building a robust sales and marketing network. Over the years, it diversified into the consumer healthcare segment with popular brands. A significant milestone was its successful Initial Public Offering (IPO) in May 2023, listing on NSE and BSE and further cementing its position as a major player in the Indian pharmaceutical industry.

Business Segments and Revenue Mix

• Pharmaceutical Formulations: Primarily focuses on the domestic market, offering a broad spectrum of prescription medicines across key therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, central nervous system, and respiratory, catering to diverse healthcare needs.

• Consumer Healthcare: Engaged in manufacturing and marketing popular over-the-counter (OTC) and fast-moving consumer goods (FMCG) brands like Manforce (condoms), Prega News (pregnancy detection kits), Gas-O-Fast (antacids), Unwanted 72 (emergency contraceptive), and Acnestar (anti-acne products).

Key Personnel

Ramesh C. Juneja - Chairman: Co-founder and a seasoned visionary, he has played a pivotal role in shaping Mankind Pharma's growth and strategic direction over decades. Rajeev Juneja - Vice Chairman & Managing Director: Co-founder, he is instrumental in building the company's extensive sales and distribution network and driving its market leadership. Sheetal Arora - Chief Executive Officer (CEO): Leads the company's day-to-day operations, focusing on strategic execution, innovation, and sustainable business growth.

Subsidiaries and Associate Companies

• Mankind Innovations Private Limited

• Magnet Labs Private Limited

• Lifestar Pharma Private Limited

• Mankind Overseas Private Limited

Corporate Actions

Successfully completed its Initial Public Offering (IPO) in May 2023, raising approx. ₹4,326 Crores.

References

1. Annual Report FY2023-24 2. Exchange Filings (NSE/BSE) 3. Investor Presentations & Financial Results 4. Company Website